Search Result

Results for "

lung cancer PDX models

" in MedChemExpress (MCE) Product Catalog:

By Targets:	17β-HSD (1) ADC Antibody (1) Antibody-Drug Conjugates (ADCs) (2) Apoptosis (4) C-type Lectin-like Receptors (CTLRs) (1) CD3 (1) CDK (1) Cuproptosis (1) Drug Intermediate (1) Drug-Linker Conjugates for ADC (1) EGFR (2) ERK (1) FAP (1) Fc Receptor (FcR) (1) Ferroptosis (1) FGFR (1) Histone Methyltransferase (1) JNK (1) Necroptosis (1) Topoisomerase (1) TROP2 (2)
By Research Areas:	Cancer (12) Inflammation/Immunology (2)

Inhibitors & Agonists

Fluorescent Dyes

Inhibitory Antibodies

Natural
Products

Targets Recommended: BCRP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-141598

Datopotamab deruxtecan (solution) 2 Publications Verification DS-1062 (solution); Dato-DXd (solution)	TROP2 Antibody-Drug Conjugates (ADCs) Topoisomerase	Cancer
Datopotamab deruxtecan (DS-1062) solution is a TROP2-targeted antibody-drug conjugate (ADC) with human TROP2 K_d of 0.74 nmol/L. Datopotamab deruxtecan solution consists of the antibody Datopotamab (HY-P99843) and the toxic molecule-linker conjugate Deruxtecan (HY-13631E). Datopotamab deruxtecan solution binds TROP2, triggers internalization and lysosomal trafficking and releases DXd topoisomerase I inhibitor payload. Datopotamab deruxtecan solution disrupts DNA function, induces DNA damage, apoptosis, and bystander killing of tumor microenvironment cells. Datopotamab deruxtecan solution can be used in research related to triple-negative breast cancer, gastric cancer, and non-small cell lung cancer .

HY-P991372

Anti-TROP2 Antibody RN927C antibody	TROP2	Cancer
Anti-TROP2 Antibody (RN927C antibody) is a human monoclonal antibody targeting Trop-2. Anti-TROP2 Antibody exerts in vitro inhibitory effects on a variety of tumor cell lines. Anti-TROP2 Antibody exhibits anti-tumor activity in mouse pancreatic PDX, ovarian PDX, lung PDX and triple-negative breast cancer (TNB) PDX models. Anti-TROP2 Antibody can be used for research on pancreatic cancer, ovarian cancer, lung cancer and triple-negative breast cancer .

HY-N5112A

β,β-Dimethylacrylalkannin 3 Publications Verification Arnebin 1	FGFR Necroptosis Apoptosis CDK JNK	Inflammation/Immunology
β,β-Dimethylacrylalkannin (Arnebin 1) is an orally active FGFR1 inhibitor (IC₅₀=2.5 μM) and the main active component of Lithospermum erythrorhizon. β,β-Dimethylacrylalkannin blocks downstream signaling by binding to the ATP pocket of FGFR1, and regulates the CDK1/Cdc25C pathway and ROS-JNK axis, thereby inducing G2/M phase arrest, necrosis and apoptosis in cancer cells, and inhibiting tumor proliferation. β,β-Dimethylacrylalkannin also acts as a colistin adjuvant to disrupt the cell membrane of Gram-negative bacteria. β,β-Dimethylacrylalkannin exhibits significant tumor-inhibitory effects with no obvious toxicity in PDX models, but chronic exposure to high doses may alter the relative lung/liver weights of rats, while acute exposure to high doses causes responses such as reduced motor activity. β,β-Dimethylacrylalkannin finds wide application in studies related to hepatocellular carcinoma, colorectal cancer, colistin-resistant bacterial infections, hepatitis and psoriasis .

HY-157229

STX-721 1 Publications Verification	EGFR ERK	Cancer
STX-721 is an orally active, irreversible, covalent EGFR exon 20 insertion (ex20ins) inhibitor that selectively targets ex20ins-mutant dynamic protein states. STX-721 potently inhibits the kinase activity of EGFR ex20ins mutants (NPG, ASV, SVD). STX-721 inhibits phosphorylation of EGFR (pEGFR Y1068) and downstream ERK (pERK Thr202/Tyr204), and suppresses proliferation of ex20ins-mutant Ba/F3 cells and human NSCLC cell lines (NCI-H2073 ASV KI, CUTO-14 ASV). STX-721 induces tumor regression in EGFR ex20ins-mutant PDX/CDX models. STX-721 can be used for the study of non-small cell lung cancer (NSCLC) harboring EGFR or HER2 ex20ins mutations .

HY-P990953

Zubotamig Gen1047	CD3	Cancer
Zubotamig (Gen1047) is an CD3E/VTCN1-targeting Ig(G1 -κ_G1 -λ2) type chimeric human antibody. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). Zubotamig induces T-cell mediated cytotoxicity of B7H4-positive tumor cells, triggers T-cell activation, and induces cytokine release from T cells in the presence of B7H4-expressing tumor cells. Zubotamig demonstrates antitumor activity in mouse patient-derived xenograft (PDX) models. Zubotamig can be used for the research of solid cancers (including breast, ovarian and lung cancer) .

HY-149040

Odafosfamide (S)-OBI-3424; (S)-TH-3424; AST-3424	17β-HSD	Cancer
Odafosfamide ((S)-OBI-3424) is a highly selective prodrug bis-alkylating agent activated by aldehyde-keto reductase 1C3 (AKR1C3(). Odafosfamide is highly cytotoxic to cell lines with high AKR1C3 expression. Odafosfamide exhibits antitumor activity in a variety of tumors with high AKR1C3 expression (such as liver cancer, non-small cell lung cancer, and leukemia). Odafosfamide can be used in cancer research .

HY-158143

AZD3470	Histone Methyltransferase Apoptosis	Cancer
AZD3470 is an orally active MTA-cooperative PRMT5 inhibitor, selective for MTAP-deficient tumors. AZD3470 induces cell cycle G₂/M phase alterations, DNA damage, apoptosis, and symmetric dimethylarginine reduction. AZD3470 alters alternative splicing, increases skipped exon events in DNA repair and cell cycle pathways, and inhibits cancer cell proliferation and tumor growth. AZD3470 can be used for the research of non-small cell lung cancer and MTAP-deleted solid tumors .

HY-149695

EGFR-IN-91	EGFR	Cancer
EGFR-IN-91 (compound 9) is an orally available EGFR inhibitor with blood-brain barrier penetrability. EGFR-IN-91 inhibits EGFR ^L858R/C797S and EGFR ^{exon 19del/C797S}, inducing tumor regression in xenograft (PDX) mouse models. EGFR-IN-91 has the potential to inhibit localized and metastatic non-small cell lung cancer (NSCLC) driven by EGFR mutants .

HY-171509

Mal-N(Me)-C6-N(Me)-PNU-159682	Drug-Linker Conjugates for ADC Apoptosis	Cancer
Mal-N(Me)-C6-N(Me)-PNU-159682 (Compound 27), an agent-linker conjugate for ADC, consists the ADC linker Mal-N(Me)-C6-N(Me) and a potent ADC cytotoxin PNU-159682. Mal-N(Me)-C6-N(Me)-PNU-159682 (Compound 27) selectively delivers the payload to CD46-expressing cells, where the linker is cleaved by cathepsin B to release PNU-159682, inducing DNA damage and apoptosis. Mal-N(Me)-C6-N(Me)-PNU-159682 shows durable tumor regression in xenograft (PDX) models of non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) .

HY-182918

DMAPT-DTCs-1,3-diaminopropane-DTCs-DMAPT dimethanesulfonate	Drug Intermediate Apoptosis Ferroptosis Cuproptosis	Cancer
DMAPT-DTCs-1,3-diaminopropane-DTCs-DMAPT dimethanesulfonate is an orally active prodrug of MMB-DTCs-1,3-diaminopropane-DTCs-MMB (HY-182917). DMAPT-DTCs-1,3-diaminopropane-DTCs-DMAPT dimethanesulfonate induces apoptosis, ferroptosis, and cuproptosis in lung cancer cells. DMAPT-DTCs-1,3-diaminopropane-DTCs-DMAPT dimethanesulfonate can be used in the research of lung cancer .

HY-P992163

23ME-01473	Fc Receptor (FcR) C-type Lectin-like Receptors (CTLRs)	Inflammation/Immunology Cancer
23ME-01473 is an anti-ULBP6/2/5 antibody with enhanced Fc effector function, with a K_d of 0.053 nmol/L against hULBP6, 0.23 nmol/L against hULBP2, and 1.92 nmol/L against hULBP5. 23ME-01473 restores anti-tumor immunity by activating NKG2D and FcγRIIIa. 23ME-01473 exerts anti-cancer activity in non-small cell lung cancer PDX models. 23ME-01473 can be used for the research of non-small cell lung cancer .

HY-P991995

OMTX005 OMTX705 antibody	ADC Antibody FAP	Cancer
OMTX005 (OMTX705 antibody) is a humanized anti-FAP IgG1 monoclonal antibody that specifically binds to human (EC₅₀: 0.33 nM)/mouse (EC₅₀: 0.14 nM) FAP proteins and FAP-positive cells. OMTX005 exhibits no cytotoxicity when used alone and fails to induce an increase in caspase 3/7 activity in relevant cells. OMTX005 can be used to synthesize the ADC molecule OMTX705 for tumor research .

HY-185426

ABBV-011 SC-011	Antibody-Drug Conjugates (ADCs)	Cancer
ABBV-011 (SC-011) is a SEZ6-targeted, antibody-drug conjugate (ADC). ABBV-011 binds cell surface-expressed SEZ6 by anti-SEZ6 antibody Turmetabart (HY-P991041), triggers ADC-receptor complex internalization into lysosomes, releases Calicheamicin (HY-19609) payload, and mediates cytotoxicity. ABBV-011 induces tumor regression and mediates selective killing of SEZ6-positive cells. ABBV-011 can be used for the research of small cell lung cancer .

Cat. No.	Product Name	Type

HY-141598

Datopotamab deruxtecan (solution) 2 Publications Verification DS-1062 (solution); Dato-DXd (solution)	Fluorescent Dyes
Datopotamab deruxtecan (DS-1062) solution is a TROP2-targeted antibody-drug conjugate (ADC) with human TROP2 K_d of 0.74 nmol/L. Datopotamab deruxtecan solution consists of the antibody Datopotamab (HY-P99843) and the toxic molecule-linker conjugate Deruxtecan (HY-13631E). Datopotamab deruxtecan solution binds TROP2, triggers internalization and lysosomal trafficking and releases DXd topoisomerase I inhibitor payload. Datopotamab deruxtecan solution disrupts DNA function, induces DNA damage, apoptosis, and bystander killing of tumor microenvironment cells. Datopotamab deruxtecan solution can be used in research related to triple-negative breast cancer, gastric cancer, and non-small cell lung cancer .

Datopotamab deruxtecan (solution)

2 Publications Verification

DS-1062 (solution); Dato-DXd (solution)

Fluorescent Dyes

Datopotamab deruxtecan (DS-1062) solution is a TROP2-targeted antibody-drug conjugate (ADC) with human TROP2 K_d of 0.74 nmol/L. Datopotamab deruxtecan solution consists of the antibody Datopotamab (HY-P99843) and the toxic molecule-linker conjugate Deruxtecan (HY-13631E). Datopotamab deruxtecan solution binds TROP2, triggers internalization and lysosomal trafficking and releases DXd topoisomerase I inhibitor payload. Datopotamab deruxtecan solution disrupts DNA function, induces DNA damage, apoptosis, and bystander killing of tumor microenvironment cells. Datopotamab deruxtecan solution can be used in research related to triple-negative breast cancer, gastric cancer, and non-small cell lung cancer .

Cat. No.	Product Name	Target	Research Area	Image

HY-P991372

Anti-TROP2 Antibody RN927C antibody	TROP2	Cancer
Anti-TROP2 Antibody (RN927C antibody) is a human monoclonal antibody targeting Trop-2. Anti-TROP2 Antibody exerts in vitro inhibitory effects on a variety of tumor cell lines. Anti-TROP2 Antibody exhibits anti-tumor activity in mouse pancreatic PDX, ovarian PDX, lung PDX and triple-negative breast cancer (TNB) PDX models. Anti-TROP2 Antibody can be used for research on pancreatic cancer, ovarian cancer, lung cancer and triple-negative breast cancer .

HY-P990953

Zubotamig Gen1047	CD3	Cancer
Zubotamig (Gen1047) is an CD3E/VTCN1-targeting Ig(G1 -κ_G1 -λ2) type chimeric human antibody. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). Zubotamig induces T-cell mediated cytotoxicity of B7H4-positive tumor cells, triggers T-cell activation, and induces cytokine release from T cells in the presence of B7H4-expressing tumor cells. Zubotamig demonstrates antitumor activity in mouse patient-derived xenograft (PDX) models. Zubotamig can be used for the research of solid cancers (including breast, ovarian and lung cancer) .

HY-P992163

23ME-01473	Fc Receptor (FcR) C-type Lectin-like Receptors (CTLRs)	Inflammation/Immunology Cancer
23ME-01473 is an anti-ULBP6/2/5 antibody with enhanced Fc effector function, with a K_d of 0.053 nmol/L against hULBP6, 0.23 nmol/L against hULBP2, and 1.92 nmol/L against hULBP5. 23ME-01473 restores anti-tumor immunity by activating NKG2D and FcγRIIIa. 23ME-01473 exerts anti-cancer activity in non-small cell lung cancer PDX models. 23ME-01473 can be used for the research of non-small cell lung cancer .

HY-P991995

OMTX005 OMTX705 antibody	ADC Antibody FAP	Cancer
OMTX005 (OMTX705 antibody) is a humanized anti-FAP IgG1 monoclonal antibody that specifically binds to human (EC₅₀: 0.33 nM)/mouse (EC₅₀: 0.14 nM) FAP proteins and FAP-positive cells. OMTX005 exhibits no cytotoxicity when used alone and fails to induce an increase in caspase 3/7 activity in relevant cells. OMTX005 can be used to synthesize the ADC molecule OMTX705 for tumor research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N5112A

β,β-Dimethylacrylalkannin 3 Publications Verification Arnebin 1	Quinones Structural Classification other families Classification of Application Fields Other Diseases Plants Naphthalene Quinones Pteris livida Mett. Disease Research Fields	FGFR Necroptosis Apoptosis CDK JNK
β,β-Dimethylacrylalkannin (Arnebin 1) is an orally active FGFR1 inhibitor (IC₅₀=2.5 μM) and the main active component of Lithospermum erythrorhizon. β,β-Dimethylacrylalkannin blocks downstream signaling by binding to the ATP pocket of FGFR1, and regulates the CDK1/Cdc25C pathway and ROS-JNK axis, thereby inducing G2/M phase arrest, necrosis and apoptosis in cancer cells, and inhibiting tumor proliferation. β,β-Dimethylacrylalkannin also acts as a colistin adjuvant to disrupt the cell membrane of Gram-negative bacteria. β,β-Dimethylacrylalkannin exhibits significant tumor-inhibitory effects with no obvious toxicity in PDX models, but chronic exposure to high doses may alter the relative lung/liver weights of rats, while acute exposure to high doses causes responses such as reduced motor activity. β,β-Dimethylacrylalkannin finds wide application in studies related to hepatocellular carcinoma, colorectal cancer, colistin-resistant bacterial infections, hepatitis and psoriasis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

lung cancer PDX models

Inhibitors & Agonists

Fluorescent Dyes

Inhibitory Antibodies

NaturalProducts

Natural
Products